Innovent Biologics stock
Price history
−6.17% over the period1 year: from $90.80 (November 17, 2025) to $85.20 (November 17, 2026), −6.17%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $85.20 |
| October 30, 2026 | $79.75 |
| September 30, 2026 | $98.05 |
| August 31, 2026 | $103.80 |
| July 31, 2026 | $86.70 |
| June 30, 2026 | $79.60 |
| May 29, 2026 | $83.35 |
| April 30, 2026 | $90.00 |
| March 31, 2026 | $84.90 |
| February 27, 2026 | $85.10 |
| January 30, 2026 | $81.10 |
| December 31, 2025 | $76.25 |
| November 28, 2025 | $94.10 |
| November 17, 2025 | $90.80 |
At a glance
The company
Biopharmaceutical company discovering and developing monoclonal antibodies and protein medicines for oncology, ophthalmology, autoimmune, cardiovascular and metabolic diseases
Latest results
Quarter to June 30, 2025 · EPS ¥0.49 (estimate ¥0.26)
TickerLandia's take on Innovent Biologics
- Pricier than similar companies: trailing 12-month P/E 112 vs 40 (+179%) in a group of 8.
- Strong point: Growth (73/100 in its group). Weak point: Earnings stability (41/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−23.87% from the 52-week high
Analysts · 29 analysts
Average target$130.22+51.77% vs. price
Buy 27 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: Innovent Biologics
Compared with similar companies: high growth and high price.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricehigh68
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 71.9 86 Price/book 6.04 53 Price/sales 9.41 50 P/E (trailing 12 months) 111.5 88 Forward P/E 33.6 66 Profitabilityaverage42
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 76.5% 52 Operating margin 7.4% 37 Net margin 7.8% 48 ROE 7.0% 37 ROA 2.2% 39 Earnings stabilityaverage41
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 34.3% 51 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthhigh73
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +44.80% 73 Earnings growth (year over year) +42.90% 76 Average revenue growth (3 years) +41.98% 69 Financial strengthaverage58
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.68 37 Debt/equitycounts in reverse: lower means more financial strength 0.11 53 Interest coverage 9.22 45 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −11.1 99 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage50
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −4.25% 39 Relative strength (6 months) +13.56% 74 1-year return −6.17% 36 Distance from 200-day average −2.96% 51 Riskaverage59
How much the price swings.
Metric Value Position in group Volatility (60 days) 45.0% 65 Beta (1 year) 1.32 77 Maximum drawdown (12 months) 27.7% 36
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Innovent Biologics is pricier than similar companies
Innovent Biologics's P/E (trailing 12 months): 111.5, +179% against the median of a group of 8 similar companies (40.0).
Compared with 8 similar companies
| Metric | Innovent Biologics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 111.5 | High | |
| Forward P/E | 33.6 | Middle | |
| Operating margin | 7.4% | Low | |
| ROE | 7.0% | Middle | |
| Debt/equity | 0.11 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Innovent Biologics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥8.62B
Latest quarter · Q2 2026
Net income
¥1.25B
Latest quarter · Q2 2026
Quarterly net margin
14.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $147.79B
- P/E
- 111.5
- EPS
- $0.76
- Volume
- 6.7M
- Daily trading
- €108.43M
- Dividend yield
- 0.00%
How Innovent Biologics is changing
All resultsRevenue grew 27.7% a year on average over the last 5 years
Operating margin rose from −68.5% to 5.6%
Shares outstanding up 28.3% in 5 years
Returns
Innovent Biologics returns
$1,000 invested in Innovent Biologics 5 years ago, on November 17, 2021, would be worth $1,066 today: +6.57% in total, +1.28% per year. This is the price return only: dividends are excluded.
| Period | Innovent Biologics | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −2.52% | −1.51% | $975 |
| 6 months | +4.63% | −8.51% | $1,046 |
| Year to date | +11.74% | −8.28% | $1,117 |
| 1 year | −6.17% | −10.90% | $938 |
| 3 years | +90.82% | +34.68% | $1,908 |
| 5 years | +6.57% | −8.35% | $1,066 |
Over the last 6 months it has done better than 49% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Innovent Biologics: technical analysis
Innovent Biologics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 21.9% below its all-time closing high ($109.80, August 26, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 48
- Between 30 and 70
- vs 200-session average
- −2.28%
Support and resistance
Price areas where Innovent Biologics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$99.61+16.10%4 touches, last on October 6, 2026
- Resistance$93.60+9.09%8 touches, last on August 17, 2026
- Resistance$90.77+5.80%2 touches, last on November 5, 2026
- Last price$85.80
- Support$84.70−1.28%4 touches, last on August 3, 2026
- Support$78.17−8.89%2 touches, last on November 2, 2026
- Support$75.97−11.46%5 touches, last on May 28, 2026
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.32
- Volatility (60 sessions, annualised)
- 45.1%
- Largest fall in the last year
- −27.73%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Innovent Biologics: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Innovent Biologics has been June: +11.61% on average, positive in 5 years out of 8. The weakest has been October: −4.33% on average, positive in 2 years out of 8. November, the current month, has been positive in 5 years out of 8 (+7.92% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −4.24% | −1.93% | 4 of 8 |
| February | +11.02% | +12.45% | 6 of 8 |
| March | −1.93% | −4.53% | 2 of 8 |
| April | +4.32% | +6.28% | 6 of 8 |
| May | +1.47% | −2.59% | 3 of 8 |
| June | +11.61% | +7.28% | 5 of 8 |
| July | +1.99% | +0.59% | 4 of 8 |
| August | +2.48% | +1.79% | 6 of 8 |
| September | +2.12% | +4.25% | 4 of 8 |
| October | −4.33% | −5.88% | 2 of 8 |
| November | +7.92% | +9.21% | 5 of 8 |
| December | +2.62% | −3.95% | 3 of 8 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Innovent Biologics and its competitors
TYVYT, BYVASDA, SULINNO and Cyramza are among the brands through which Innovent Biologics, Inc. is best known, alongside Retsevmo and Jaypirca. The company works on antibody and protein medicines and takes them from discovery through manufacturing to sale, with therapies aimed at cancer, eye diseases, autoimmune conditions, heart disease and metabolic disorders. Besides its own portfolio, it distributes pharmaceutical products and provides consulting and research and development services. Its activity spans mainland China, the United States and Europe, as well as other international markets.
- Headquarters
- Suzhou, China
- Employees
- 8,754
- Founded
- 2011
- Chief executive
- De-Chao Yu
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Innovent Biologics1801 | $18.84B | 7.4% | 111.5 | +4.63% |
| WuXi Biologics (Cayman)2269 | $24.52B | 32.4% | 35.1 | +37.47% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | −0.50% |
| Sino Biopharmaceutical1177 | $12.49B | 28.2% | 36.7 | +1.30% |
| Pharmaron Beijing300759 | $11.45B | 14.0% | 42.4 | +53.82% |
| Haisco Pharmaceutical Group002653 | $9.93B | 21.1% | 48.8 | +2.51% |
Same industry or related industries, similar size. Compare Innovent Biologics with its competitors · Full profile
